The US Food and Drug Administration (FDA) has granted Fast Track Group (NASDAQ:FTRK) designation to CK0803, an investigational cell therapy developed by Cellenkos to treat amyotrophic lateral sclerosis (ALS).
Cellenkos, the clinical-stage biotechnology company based in Houston, announced that the regulatory decision aims to accelerate the clinical development and review of the experimental treatment.
Amyotrophic lateral sclerosis is a fatal neurodegenerative disorder where median patient survival is typically between two and three years from the onset of symptoms.
The Fast Track program enables drug developers to hold more frequent meetings with regulators and to have completed sections of a Biologics License Application (BLA) reviewed on an ongoing basis.
The therapy uses regulatory T-cells (Tregs), which are specialized immune cells harvested from healthy donor umbilical cord blood to suppress chronic inflammation in the central nervous system.
Scientists engineered the donor cells to cross the protective barrier surrounding the brain and spinal cord, targeting inflamed tissues directly without requiring chemotherapy conditioning or tissue matching.
Early data from an ongoing Phase I/Ib clinical trial involving six patients showed that the treatment stabilized functional decline on a standard clinical rating scale.
Patients receiving up to 9 infusions of 100 million cells experienced an approximately 60% decrease in plasma neurofilament light chain levels, a biological marker of nerve cell damage.
The study also documented an approximate 200% increase in interleukin-10, an anti-inflammatory protein that helps restore immune balance.
The company reported that no dose-limiting toxicities occurred during the ongoing safety evaluation.
Cellenkos stated that the biological mechanism behind the therapy could potentially apply to other neurodegenerative conditions, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
Any future clinical trials for additional neurodegenerative disorders will depend on further laboratory testing, regulatory discussions, and available funding.